The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3

Cancer Research

Volumn 70, Issue 4, 2010, Pages 1573-1584

  Guise, Christopher P ^a   Abbattista, Maria R ^a   Singleton, Rachelle S ^a   Holford, Samuel D ^a   Connolly, Joanna ^a   Dachs, Gabi U ^b   Fox, Stephen B ^c   Pollock, Robert ^d   Harvey, Justin ^d   Guilford, Parry ^d   Doñate, Fernando ^e   Wilson, William R ^a   Patterson, Adam V ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d Pacific Edge Biotechnology Ltd   (New Zealand)

^e Proacta Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETO REDUCTASE 1C3; DNA; NITROREDUCTASE; ORGANOPHOSPHATE; OXYGEN; PR 104A; PRODRUG; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOGENESIS; CANCER INHIBITION; CYTOTOXICITY; DNA CROSS LINKING; DRUG ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; HYPOXIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METABOLITE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENIC OSTEOMALACIA; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; TISSUE MICROARRAY; TUMOR; TUMOR CELL LINE; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

3-HYDROXYSTEROID DEHYDROGENASES; AEROBIOSIS; ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NITROGEN MUSTARD COMPOUNDS; OXIDATION-REDUCTION; OXYGEN; PRODRUGS; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76749161362     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3237     Document Type: Article

References (44)

1. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DTdiaphorase), functions and pharmacogenetics. Methods Enzymol 2004;382:115-44.
2. Knox RJ, Chen S. Quinone reductase-mediated nitro-reduction: clinical applications. Methods Enzymol 2004;382:194-221.
3. Minn H, Gronroos TJ, Komar G, et al. Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des 2008;14:2932-42.
4. Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev 2008;29:29-64.
5. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
6. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39.
7. Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res 2007;13:3922-32.
8. Guise CP, Wang A, Thiel A, et al. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 2007;74:810-20.
9. Hicks KO, Myint H, Patterson AV, et al. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 2007;69:560-71.
10. Jameson MB, Rischin D, Pegram M, et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 2010. DOI: 10.1007/s00280-009-1188-1.
11. SingletonRS, Guise CP, FerryDM, et al.DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity. Cancer Res 2009;69:3884-91.
12. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116.
13. Liu Y, Kern JT, Walker JR, et al. A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A 2007; 104:5205-10.
14. Penning TM, Drury JE. Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys 2007;464:241-50.
15. Yang S, Atwell GJ, Denny WA. Synthesis of asymmetric halomesylate mustards with aziridineethanol/alkali metal halides: application to an improved synthesis of the hypoxia prodrug PR-104. Tetrahedron 2007;63:5470-6.
16. 2H4- labelled versions of the hypoxia-activated pre-prodrug 2-[(2-bromoethyl)-2,4- dinitro-6-[[[2-(phosphonooxy)ethyl]amino]carbonyl]anilino]ethyl methanesulfonate (PR-104). J Labelled Comp Radiopharm 2007;50:7-12.
17. Wilson WR, Hicks KO, Pullen SM, et al. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 2007;167: 625-36.
18. Gentleman R, Carey V, Ber W. Bioinformatics and computational biology solutions using R and Bioconductor. In: Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S, editors. New York: Springer-Verlag New York, Inc.; 2005.
19. Loennstedt I, Speed TP. Replicated microarray data. Stat Sin 2002; 12:31-46.
20. Hobbs S, Jitrapakdee S, Wallace JC. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1á promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 1998;252:368-72.
21. Ahn GO, Botting KJ, Patterson AV, et al. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem Pharmacol 2006;71:1683-94.
22. Halim M, Yee DJ, Sames D. Imaging induction of cytoprotective enzymes in intact human cells: coumberone, a metabolic reporter for human AKR1C enzymes reveals activation by panaxytriol, an active component of red ginseng. J Am Chem Soc 2008;130: 14123-8.
23. Lin HK, Steckelbroeck S, Fung KM, Jones AN, Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004;69:795-801.
24. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:e420.
25. Taguchi K, Shimada M, Fujii S, et al. Redox cycling of 9,10-phenanthraquinone to cause oxidative stress is terminated through its monoglucuronide conjugation in human pulmonary epithelial A549 cells. Free Radic Biol Med 2008;44:1645-55.
26. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 2007;47:263-92.
27. MacLeod AK, McMahon M, Plummer SM, et al. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-2 pathway, and not the BACH1-2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 2009;30:1571-80.
28. Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 2006;21:689-700.
29. Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008;68:1303-9.
30. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 2008;68:7975.
31. Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008;29:1235-43.
32. Homma S, Ishii Y, Morishima Y, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009;15:3423-32.
33. Pelletier G, Luu-The V, Tetu B, Labrie F. Immunocytochemical localization of type 5 17β-hydroxysteroid dehydrogenase in human reproductive tissues. J Histochem Cytochem 1999;47:731-8.
34. Penning TM, Burczynski ME, Jez JM, et al. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000;351:67-77.
35. Azzarello J, Fung KM, Lin HK. Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system. J Histochem Cytochem 2008;56:853-61.
36. Birtwistle J, Hayden RE, Khanim FL, et al. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis. Mutat Res 2009;662:67-74.
37. Amin SA, Huang CC, Reierstad S, et al. Paracrine-stimulated gene expression profile favors estradiol production in breast tumors. Mol Cell Endocrinol 2006;253:44-55.
38. Oduwole OO, Li Y, Isomaa VV, et al. 17β-Hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 2004;64:7604-9.
39. Nakamura Y, Suzuki T, Nakabayashi M, et al. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005;12:101-7.
40. Wako K, Kawasaki T, Yamana K, et al. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008; 61:448-54.
41. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. Cancer Res 2006;66:2815-25.
42. Rizner TL, Smuc T, Rupreht R, Sinkovec J, Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006;248:126-35.
43. Ito K, Utsunomiya H, Suzuki T, et al. 17β-Hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006;248:136-40.
44. Sakurai M, Oishi K, Watanabe K. Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma. Biochem Biophys Res Commun 2005; 338:82-6.